Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2016

Garcia Jacqueline S, Huang Min, Medeiros Bruno C, Mitchell Beverly S

Abstract excerpt

PURPOSE: This study was performed to determine whether the investigational proteasome inhibitor ixazomib demonstrated selective antineoplastic activity against acute myelogenous leukemia cells expressing a mutated nucleophosmin-1 gene and to gain a better understanding of its mechanisms of action. EXPERIMENTAL DESIGN: The cytotoxic effects of ixazomib treatment were analyzed in human acute myelogenous leukemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Boron Compounds
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutathione

Share to Glycine

Share to Histone Deacetylase Inhibitors

Share to Immunophenotyping

Share to Nucleophosmin

Share to Superoxides

Source

Identifiers

PMID: 26634271
DOI: 10.1158/1078-0432.CCR-15-1440

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.PMID 26634271Read ↗

Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.Semantic proximity Read ↗

Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.Semantic proximity Read ↗

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.Semantic proximity Read ↗

FOXM1 contributes to treatment failure in acute myeloid leukemia.Semantic proximity Read ↗

Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.Semantic proximity Read ↗

Knockdown of BNIP3L or SQSTM1 alters cellular response to mitochondria target drugsSemantic proximity Read ↗

Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.Semantic proximity Read ↗

Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.Semantic proximity Read ↗

The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.Semantic proximity Read ↗

The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabineSemantic proximity Read ↗

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in <i>NPM1</i> -mutated AMLSemantic proximity Read ↗

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.